Top

Published in:

01-09-2009 | Original Communication

Efficacy of anti-epileptic drugs in patients with gliomas and seizures

Authors: Mèlanie S. M. van Breemen, R. M. Rijsman, M. J. B. Taphoorn, R. Walchenbach, H. Zwinkels, Charles J. Vecht

Published in: Journal of Neurology | Issue 9/2009

Abstract

Although seizures in brain tumor patients are common, the knowledge on optimal anti-seizure therapy in this patient group is limited. An observational study was carried out using a database of all patients from the neuro-oncology service during the period 2000–2005, with data on seizure characteristics, therapy with AEDs, the underlying brain tumor and its treatment. A total of 140 brain tumor patients were studied of whom 23.6% had a low-grade glioma, 53.6% a high-grade glioma, and 22.8% belonged to a mixed group existing of ependymoma, meningioma, and brain metastasis. Epilepsy as the presenting sign was more frequent in low-grade vs. high-grade gliomas (69.7 vs. 52%, P = 0.087), and a total of 75.8% of patients developed seizures with low-grade and of 80.0% with high-grade gliomas. Of all 99 patients with seizures, 80.1% received valproic acid (VPA) as first choice, and either levetiracetam (LEV), carbamazepine (CBZ) or lamotrigine (LMT) as the most frequent next choice. Patients treated with a combination of VPA and LEV showed the highest percentage of responders (81.5%), with a decline in seizure frequency of more than two categories in 55.6% and seizure freedom in 59%. No correlation was found between the use of VPA and survival. A combination of VPA and LEV seems effective, if seizure control cannot be achieved by VPA alone. This indicates that adding levetiracetam may be preferable over sequential trials of AED monotherapy in treatment-resistant seizures in patients with brain tumors.

Moots PL, Maciunas RJ, Eisert DR, Parker RA, Laporte K, Abou-Khalil B (1995) The course of seizure disorders in patients with malignant gliomas. Arch Neurol 52:717–724PubMed

van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 6:421–430. doi:10.1016/S1474-4422(07)70103-5 PubMedCrossRef

Hildebrand JF, Lecaille CF, Perennes JF, Delattre JY (2005) Epileptic seizures during follow-up of patients treated for primary brain tumors. Neurology 65:212–215. doi:10.1212/01.wnl.0000168903.09277.8f PubMedCrossRef

Wick W, Menn O, Meisner C, Steinbach J, Hermisson M, Tatagiba M, Weller M (2005) Pharmacotherapy of epileptic seizures in glioma patients: who, when, why and how long? Onkologie 28:391–396. doi:10.1159/000086375 PubMedCrossRef

Wagner GL, Wilms EB, Van Donselaar CA, Vecht C (2003) Levetiracetam: preliminary experience in patients with primary brain tumours. Seizure 12:585–586. doi:10.1016/S1059-1311(03)00096-7 PubMedCrossRef

Eyal S, Yagen B, Sobol E, Altschuler Y, Shmuel M, Bialer M (2004) The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia 45:737–744. doi:10.1111/j.0013-9580.2004.00104.x PubMedCrossRef

Li XN, Shu Q, Su JM, Perlaky L, Blaney SM, Lau CC (2005) Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC. Mol Cancer Ther 4:1912–1922. doi:10.1158/1535-7163.MCT-05-0184 PubMedCrossRef

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109. doi:10.1007/s00401-007-0243-4 PubMedCrossRef

Chavez-Blanco A, Perez-Plasencia C, Perez-Cardenas E, Carrasco-Legleu C, Rangel-Lopez E, Segura-Pacheco B, Taja-Chayeb L, Trejo-Becerril C, Gonzalez-Fierro A, Candelaria M, Cabrera G, Duenas-Gonzalez A (2006) Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. Cancer Cell Int 6(2):22–31. doi:10.1186/1475-2867-6-2 PubMed

10.

Norden AD, Wen PY (2006) Glioma therapy in adults. Neurologist 12:279–292. doi:10.1097/01.nrl.0000250928.26044.47 PubMedCrossRef

11.

Stupp RF, Mason WPFAU, van den Bent M, van den Bent MJFAU, Weller M, Weller MF, Fisher BF, Taphoorn MJFAU, Belanger K, Belanger KF, Brandes AAFAU, Marosi C, Marosi CF, Bogdahn UF, Curschmann JF, Janzer RCFAU, Ludwin S, Ludwin SKFAU, Gorlia T, Gorlia TF, Allgeier AF, Lacombe DF, Cairncross JGFAU, Eisenhauer E, Eisenhauer EFAU, Mirimanoff R, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 10:987–996. doi:10.1056/NEJMoa043330

12.

Van der Sanden GA, Schouten LJ, van Dijck JA, van Andel JP, van der Maazen RW, Coebergh JW (2002) Primary central nervous system lymphomas: incidence and survival in the Southern and Eastern Netherlands. Cancer 94:1548–1556. doi:10.1002/cncr.10357 PubMedCrossRef

13.

Herman ST (2002) Epilepsy after brain insult: targeting epileptogenesis. Neurology 59:S21–S26PubMed

14.

Cascino GD (1990) Epilepsy and brain tumors: implications for treatment. Epilepsia 31(Suppl 3):S37–S44. doi:10.1111/j.1528-1157.1990.tb05858.x PubMedCrossRef

15.

Bootsma HP, Ricker L, Diepman L, Gehring J, Hulsman J, Lambrechts D, Leenen L, Majoie M, Schellekens A, de Krom M, Aldenkamp AP (2007) Levetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. Epilepsy Behav 10:296–303. doi:10.1016/j.yebeh.2006.11.016 PubMedCrossRef

16.

Genton P, Sadzot B, Fejerman N, Peltola J, Despland PA, Steinhoff B, Rektor I, Wroe S, Maubrey MC, Vandervelden C, van Hammee G, Schlit AF, van Paesschen W (2006) Levetiracetam in a broad population of patients with refractory epilepsy: interim results of the international SKATE trial. Acta Neurol Scand 113:387–394. doi:10.1111/j.1600-0404.2006.00647.x PubMedCrossRef

17.

Kinirons P, McCarthy M, Doherty CP, Delanty N (2006) Predicting drug-resistant patients who respond to add-on therapy with levetiracetam. Seizure 15:387–392. doi:10.1016/j.seizure.2006.05.001 PubMedCrossRef

18.

Brodie MJ, Stephen LJ (2007) Outcomes in elderly patients with newly diagnosed and treated epilepsy. Int Rev Neurobiol 81:253–263. doi:10.1016/S0074-7742(06)81016-0 PubMedCrossRef

19.

Hermann DM, Kilic E, Spudich A, Kramer SD, Wunderli-Allenspach H, Bassetti CL (2006) Role of drug efflux carriers in the healthy and diseased brain. Ann Neurol 60:489–498. doi:10.1002/ana.21012 PubMedCrossRef

20.

Calatozzolo C, Gelati M, Ciusani E, Sciacca FL, Pollo B, Cajola L, Marras C, Silvani A, Vitellaro-Zuccarello L, Croci D, Boiardi A, Salmaggi A (2005) Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-pi in human glioma. J Neurooncol 74:113–121. doi:10.1007/s11060-004-6152-7 PubMedCrossRef

21.

Coupez R, Nicolas JM, Browne TR (2003) Levetiracetam, a new antiepileptic agent: lack of in vitro and in vivo pharmacokinetic interaction with valproic acid. Epilepsia 44:171–178. doi:10.1046/j.1528-1157.2003.25302.x PubMedCrossRef

22.

Vecht CJ, Wagner GL, Wilms EB (2003) Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol 2:404–409. doi:10.1016/S1474-4422(03)00435-6 PubMedCrossRef

23.

Maschio M, Albani F, Baruzzi A, Zarabla A, Dinapoli L, Pace A, Pompili A, Carapella CM, Occhipinti E, Jandolo B (2006) Levetiracetam therapy in patients with brain tumour and epilepsy. J Neurooncol 80:97–100. doi:10.1007/s11060-006-9162-9 PubMedCrossRef

24.

Newton HB, Goldlust SA, Pearl D (2006) Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients. J Neurooncol 78:99–102. doi:10.1007/s11060-005-9070-4 PubMedCrossRef

25.

Lynam LM, Lyons MK, Drazkowski JF, Sirven JI, Noe KH, Zimmerman RS, Wilkens JA (2007) Frequency of seizures in patients with newly diagnosed brain tumors: a retrospective review. Clin Neurol Neurosurg 109:634–638. doi:10.1016/j.clineuro.2007.05.017 PubMedCrossRef

26.

Otoul C, Arrigo C, Van Rijckevorsel K, French JA (2005) Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy. Clin Neuropharmacol 28:72–78. doi:10.1097/01.wnf.0000159956.87511.67 PubMedCrossRef

27.

Van Rijckevorsel K, Boon PA (2001) The ‘number needed to treat’ with Levetiracetam (LEV): comparison with the other new antiepileptic drugs (AEDs). Seizure 10:235–236. doi:10.1053/seiz.2001.0497 PubMedCrossRef

28.

Van den Bent MJ, Reni M, Gatta G, Vecht C (2008) Oligodendroglioma. Crit Rev Oncol Hematol 66:262–272. doi:10.1016/j.critrevonc.2007.11.007 PubMedCrossRef

29.

Van Veelen ML, Avezaat CJ, Kros JM, van Putten W, Vecht C (1998) Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation, and the issue of early versus late surgery. J Neurol Neurosurg Psychiatry 64:581–587. doi:10.1136/jnnp.64.5.581 PubMedCrossRef

Title: Efficacy of anti-epileptic drugs in patients with gliomas and seizures
Authors: Mèlanie S. M. van Breemen
R. M. Rijsman
M. J. B. Taphoorn
R. Walchenbach
H. Zwinkels
Charles J. Vecht
Publication date: 01-09-2009
Publisher: D. Steinkopff-Verlag
Published in: Journal of Neurology / Issue 9/2009
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-009-5156-9

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Efficacy of anti-epileptic drugs in patients with gliomas and seizures

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2009

Ataxia oculomotor apraxia type 2: course over 27 years and a novel stop mutation in the senataxin gene

Acute aphasia after right hemisphere stroke

Prevalence and definition of drooling in Parkinson’s disease: a systematic review

Negative studies that change our knowledge and attitudes

Why it’s important to know Percheron’s artery: solitary carotid stenosis as a unique cause of anterior, posterior and bithalamic ischemia

Novel subtype of idiopathic bilateral vestibulopathy: bilateral absence of vestibular evoked myogenic potentials in the presence of normal caloric responses